C3N-00549
— · cohortMD1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD1
- subtype
- cohortMD1
- age_years
- 58.59548255
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UNFOLDED_PROTEIN_RESPONSE+0.400
- E2F_TARGETS+0.390
- MYC_TARGETS_V2+0.380
- WNT_BETA_CATENIN_SIGNALING+0.380
- MYC_TARGETS_V1+0.340
- G2M_CHECKPOINT+0.330
- PANCREAS_BETA_CELLS+0.320
- SPERMATOGENESIS+0.230
- DNA_REPAIR+0.220
- MTORC1_SIGNALING+0.050
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.720
- INTERFERON_GAMMA_RESPONSE-0.660
- ALLOGRAFT_REJECTION-0.570
- IL6_JAK_STAT3_SIGNALING-0.570
- INFLAMMATORY_RESPONSE-0.530
- TNFA_SIGNALING_VIA_NFKB-0.510
- IL2_STAT5_SIGNALING-0.440
- COMPLEMENT-0.430
- NOTCH_SIGNALING-0.420
- APICAL_SURFACE-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2278885 | — | — | 0.934 |
| 2 | BS_JZRM1S3T | medulloblastoma | — | 0.933 |
| 3 | BS_5VQP0E6K | medulloblastoma | — | 0.931 |
| 4 | BS_HB03GSHF | medulloblastoma | — | 0.929 |
| 5 | BS_GCQFGDTX | medulloblastoma | — | 0.926 |
| 6 | TCGA-56-7223-01A-11R-2045-07 | — | cohortMD1 | 0.925 |
| 7 | BS_4D9DD103 | medulloblastoma | — | 0.918 |
| 8 | BS_BPWEFR89 | medulloblastoma | — | 0.918 |
| 9 | SRR8518260 | — | A | 0.917 |
| 10 | BS_YETBN0RQ | medulloblastoma | — | 0.917 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UNFOLDED_PROTEIN_RESPONSE | 0.400 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.390 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.380 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.380 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.340 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.330 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.320 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.230 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.220 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.050 | Inavolisib | — uncovered |